Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Jeffrey V. Poulton Sells 967 Shares

Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) CFO Jeffrey V. Poulton sold 967 shares of the stock in a transaction that occurred on Friday, February 14th. The stock was sold at an average price of $255.17, for a total value of $246,749.39. Following the transaction, the chief financial officer now owns 32,786 shares in the company, valued at approximately $8,366,003.62. This trade represents a 2.86 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through this link.

Alnylam Pharmaceuticals Trading Down 2.5 %

NASDAQ ALNY opened at $250.00 on Wednesday. The company has a quick ratio of 2.69, a current ratio of 2.75 and a debt-to-equity ratio of 31.64. Alnylam Pharmaceuticals, Inc. has a twelve month low of $141.98 and a twelve month high of $304.39. The company has a market cap of $32.25 billion, a price-to-earnings ratio of -95.42 and a beta of 0.35. The business’s fifty day moving average is $253.96 and its 200 day moving average is $263.29.

Alnylam Pharmaceuticals (NASDAQ:ALNY) last released its quarterly earnings data on Thursday, February 13th. The biopharmaceutical company reported ($0.65) earnings per share for the quarter, missing the consensus estimate of ($0.62) by ($0.03). As a group, sell-side analysts expect that Alnylam Pharmaceuticals, Inc. will post -2.24 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on ALNY. Scotiabank lowered their target price on Alnylam Pharmaceuticals from $310.00 to $300.00 and set a “sector outperform” rating on the stock in a research note on Friday, February 14th. StockNews.com downgraded Alnylam Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Thursday, January 9th. Canaccord Genuity Group increased their price target on Alnylam Pharmaceuticals from $384.00 to $385.00 and gave the stock a “buy” rating in a research report on Tuesday. Morgan Stanley increased their price target on Alnylam Pharmaceuticals from $275.00 to $284.00 and gave the stock an “equal weight” rating in a research report on Friday, February 14th. Finally, Barclays increased their price target on Alnylam Pharmaceuticals from $295.00 to $329.00 and gave the stock an “overweight” rating in a research report on Friday, November 1st. One research analyst has rated the stock with a sell rating, six have given a hold rating and nineteen have issued a buy rating to the company. According to data from MarketBeat.com, Alnylam Pharmaceuticals has an average rating of “Moderate Buy” and an average target price of $299.48.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of the stock. Allworth Financial LP raised its position in Alnylam Pharmaceuticals by 6.8% during the 4th quarter. Allworth Financial LP now owns 597 shares of the biopharmaceutical company’s stock worth $140,000 after purchasing an additional 38 shares during the last quarter. Investment Management Corp of Ontario raised its position in Alnylam Pharmaceuticals by 0.6% during the 4th quarter. Investment Management Corp of Ontario now owns 7,099 shares of the biopharmaceutical company’s stock worth $1,670,000 after purchasing an additional 40 shares during the last quarter. Nixon Peabody Trust Co. raised its position in Alnylam Pharmaceuticals by 1.9% during the 4th quarter. Nixon Peabody Trust Co. now owns 2,293 shares of the biopharmaceutical company’s stock worth $540,000 after purchasing an additional 43 shares during the last quarter. Brevan Howard Capital Management LP raised its position in Alnylam Pharmaceuticals by 3.4% during the 4th quarter. Brevan Howard Capital Management LP now owns 1,333 shares of the biopharmaceutical company’s stock worth $314,000 after purchasing an additional 44 shares during the last quarter. Finally, Huntington National Bank raised its position in Alnylam Pharmaceuticals by 91.8% during the 3rd quarter. Huntington National Bank now owns 94 shares of the biopharmaceutical company’s stock worth $26,000 after purchasing an additional 45 shares during the last quarter. 92.97% of the stock is owned by institutional investors.

Alnylam Pharmaceuticals Company Profile

Alnylam Pharmaceuticals, Inc, a biopharmaceutical company, focuses on discovering, developing, and commercializing novel therapeutics based on ribonucleic acid interference. Its marketed products include ONPATTRO (patisiran) for the treatment of the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; AMVUTTRA for the treatment of hATTR amyloidosis with polyneuropathy in adults; GIVLAARI for the treatment of adults with acute hepatic porphyria; and OXLUMO for the treatment of primary hyperoxaluria type 1.